The 7 highest-scored Biotechnology - Gene Therapy companies in the AskCyborg corpus, ranked by Cyborg Score — a 1–10 rating from a bull-vs-bear AI analyst debate across 11 dimensions. Leading the table: Neurogene Inc. (8/10), MeiraGTx Holdings plc (7/10), REGENXBIO Inc. (7/10).
| # | Company | Cyborg Score | The verdict | Ownership | Peers |
|---|---|---|---|---|---|
| 1 | Neurogene Inc. | 8/10 | Imminent registrational trial data and FDA designation suggest meaningful de-risking for a rare disease gene therapy with significant commer | Public | |
| 2 | MeiraGTx Holdings plc | 7/10 | Clinical-stage gene therapy company with validated manufacturing, strong partner validation, and multiple late-stage programs addressing hig | Public | |
| 3 | REGENXBIO Inc. | 7/10 | Late-stage AAV gene therapy company with multiple regulatory catalysts in 2026, strong partnerships, and in-house manufacturing, but facing | Public | |
| 4 | 4D Molecular Therapeutics, Inc. | 6/10 | Late-stage gene therapy company with promising lead ophthalmology program advancing toward commercial potential, supported by strategic part | Public | |
| 5 | Takara Bio Inc. | 6/10 | Positioned for growth in expanding gene therapy markets with proprietary platforms and manufacturing infrastructure, though near-term profit | Public | |
| 6 | Voyager Therapeutics, Inc. | 6/10 | Early-stage gene therapy platform targeting large neurological disease markets with encouraging preclinical data, but clinical validation an | Public | |
| 7 | Rocket Pharmaceuticals, Inc. | 5/10 | Clinical validation and regulatory progress offer upside potential, but execution risk and analyst disagreement warrant cautious approach to | Public |
See also Biotechnology - Gene Therapy industry research and the full industry ratings index.
Cyborg Scores (1–10) are synthesized by AskCyborg’s multi-agent analyst-debate framework across 11 dimensions, recalibrated weekly. How the score works · Methodology.